Detalhe da pesquisa
1.
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
J Nanobiotechnology
; 20(1): 417, 2022 Sep 19.
Artigo
Inglês
| MEDLINE | ID: mdl-36123677
2.
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
Gynecol Oncol
; 160(2): 418-426, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33243443
3.
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
J Exp Clin Cancer Res
; 43(1): 70, 2024 Mar 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38443968
4.
Molecular MRI for sensitive and specific detection of lung metastases.
Proc Natl Acad Sci U S A
; 107(8): 3693-7, 2010 Feb 23.
Artigo
Inglês
| MEDLINE | ID: mdl-20142483
5.
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
Melanoma Res
; 33(4): 332-337, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37325860
6.
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.
JCI Insight
; 8(12)2023 06 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37345658
7.
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer.
Cancer Immunol Res
; 11(4): 486-500, 2023 04 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36700864
8.
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
Front Immunol
; 13: 1022011, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36405757
9.
Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases.
Front Immunol
; 12: 812210, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34975924
10.
Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.
Mol Cancer Ther
; 19(11): 2396-2406, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32943548
11.
iDQC anisotropy map imaging for tumor tissue characterization in vivo.
Magn Reson Med
; 61(4): 937-43, 2009 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-19215050
12.
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.
Mol Cancer Ther
; 18(5): 969-979, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30926640
13.
Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate.
J Pharm Pharmacol
; 60(11): 1441-8, 2008 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-18957164
14.
Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
Hum Gene Ther
; 18(5): 457-73, 2007 May.
Artigo
Inglês
| MEDLINE | ID: mdl-17536976
15.
Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.
Mol Cell Endocrinol
; 260-262: 183-9, 2007 Jan 02.
Artigo
Inglês
| MEDLINE | ID: mdl-17101210
16.
Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.
Mol Cell Endocrinol
; 269(1-2): 26-33, 2007 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17382461
17.
Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases.
Biomaterials
; 27(9): 2001-8, 2006 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-16280161
18.
Membrane disrupting lytic peptides for cancer treatments.
Curr Pharm Des
; 10(19): 2299-310, 2004.
Artigo
Inglês
| MEDLINE | ID: mdl-15279610
19.
Efficacy of lytic peptide-bound magnetite nanoparticles in destroying breast cancer cells.
J Nanosci Nanotechnol
; 4(3): 245-9, 2004 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-15233083
20.
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.
Cancer Chemother Pharmacol
; 73(5): 931-41, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24610297